BeiGene
BGNE
#959
Rank
ยฃ15.59 B
Marketcap
ยฃ142.57
Share price
0.49%
Change (1 day)
11.41%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -ยฃ0.69 Billion

According to BeiGene 's latest financial reports the company's current earnings are ยฃ3.31 Billion. In 2023 the company made an earning of -ยฃ0.94 Billion, an increase over its 2022 earnings that were of -ยฃ1.39 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.69 Billion-26.76%
2023 -ยฃ0.94 Billion-32.52%
2022 -ยฃ1.39 Billion24.39%
2021 -ยฃ1.12 Billion-13.21%
2020 -ยฃ1.28 Billion72.69%
2019 -ยฃ0.75 Billion36.01%
2018 -ยฃ0.55 Billion616.83%
2017 -ยฃ76 Million-15.24%
2016 -ยฃ89.67 Million107.91%
2015 -ยฃ43.13 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ14.02 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ90.96 Million-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA